Pfizer children's pneumococcal vaccine approved in China

Pfizer yesterday announced that China's State Food and drug administration has officially approved the use of its Prevenar 13 vaccine to help prevent pneumococcal infection in infants and children between six and 15 weeks of age The product name of Prevenar 13 vaccine in the U.S market is prevnar 13 (photo source: Pfizer official website) Pneumococcus (also known as Streptococcus pneumoniae, Streptococcus pneumoniae) generally exists in the human nasopharynx, causing pneumonia, upper respiratory tract infection, meningitis and other diseases, which are mainly transmitted through droplets and close contact Because the immune system of infant is not well developed, it becomes the main population carrying and spreading pneumococcus If infants unfortunately infected with pneumococcus, it is easy to cause various invasive diseases, which may lead to deafness, stunting and even death According to the statistics of the World Health Organization, the diseases caused by pneumococcal infection will cause about one million children to die every year, which has become the main cause of death of children under five years old in the world Therefore, it is of great significance to popularize pneumococcal vaccine in infants ▲ pneumococcus is one of the main pathogens causing pneumonia, upper respiratory tract infection and meningitis (picture source: CDC website) Peier13 vaccine can effectively prevent the 13 serotypes (1, 3, 4, 5, 6a, 6b, 7F, 9V, 14, 18C, 19a) it covers, 23F) invasive diseases caused by pneumococcal infection, such as bacteremia pneumonia, meningitis, septicemia and bacteremia The Centers for Disease Control and Prevention recommends that all infants and young children be vaccinated four times at the age of 2, 4, 6, 12 to 15 months In China, Peier 13 vaccine is recommended to be vaccinated for three times at 2, 4 and 6 months of age, and for one time at 12-15 months of age "We thank the State Food and Drug Administration and other relevant departments for their efforts to introduce innovative drugs and vaccines into China," said Dr Wu Xiaobin, President of Pfizer China "Pfizer will continue to work closely with the State Food and Drug Administration and other relevant departments to help Chinese patients and the public improve their life-long health." Dr Wu Xiaobin, President of Pfizer China (photo source: Official Website of the Ministry of Commerce of China), hopes that the approval of the vaccine will help more children in China to avoid the threat of pneumococcal invasive diseases and bring more families peace and health.